Recombinant monoclonal antibody to EGFR. Zalutumumab (proposed trade name HuMax-EGFr) is a fully human IgG1 monoclonal antibody (mAb) directed towards the epidermal growth factor receptor (EGFr). the Netherlands. Specifically, zalutumumab is designed for the treatment of squamous cell carcinoma of the head and neck (SCCHN), a type of cancer. The current treatment for SCCHN includes tyrosine kinase inhibitors and human monoclonal antibodiess. In addition, murine mAbs were tested successfully in mice, but caused an immune response in humans and were thus determined as ineffective in therapeutics.
Figure 1 Development of a panel of EGFR-specific mAbs with distinct functionalities.
A, Binding of zalutumumab, zalu-N297Q, mAb 018, and mAb 018-N297Q to cell-associated EGFR on A431 cells analyzed by flow cytometry; data were analyzed using a four-parameter logistic curve fit. Shown is the mean fluorescence intensity (MFI). B, The capacity of the different mAbs to induce ADCC analyzed in a 51Cr-release assay using human PBMCs as effector cells and A431 cells as target cells. Data shown are percentages specific lysis, calculated as described in Materials and Methods. C, mAb-induced inhibition of EGFR phosphorylation in A431 cells upon stimulation with EGF measured in an EGFR phosphorylation inhibition assay. Data shown are time-resolved fluorescences (TRF). D, Inhibition of A431 cell proliferation determined in a proliferation inhibition assay using Alamar Blue staining. Each data point represents mean ± SEM of triplicates, and experiments shown are representative of at least two independent experiments.
Overdijk, M. B., Verploegen, S., van den Brakel, J. H., van Bueren, J. J. L., Vink, T., van de Winkel, J. G., ... & Bleeker, W. K. (2011). Epidermal growth factor receptor (EGFR) antibody-induced antibody-dependent cellular cytotoxicity plays a prominent role in inhibiting tumorigenesis, even of tumor cells insensitive to EGFR signaling inhibition. The Journal of Immunology, 1003926.
Figure 2 Zalutumumab and mAb 018 are functional in an ADCC assay with murine effector cells.
The capacity of the different mAbs to induce ADCC was analyzed in a 51Cr-release assay using mouse bone marrow-derived macrophages as effector cells, and A431 cells as target cells. mAbs were tested at a concentration of 10 μg/ml with six replicates. Data represent mean ± SEM of three independent experiments.
Overdijk, M. B., Verploegen, S., van den Brakel, J. H., van Bueren, J. J. L., Vink, T., van de Winkel, J. G., ... & Bleeker, W. K. (2011). Epidermal growth factor receptor (EGFR) antibody-induced antibody-dependent cellular cytotoxicity plays a prominent role in inhibiting tumorigenesis, even of tumor cells insensitive to EGFR signaling inhibition. The Journal of Immunology, 1003926.
Figure 3 Both zalutumumab and mAb 018 are capable of inhibiting growth of tumor cells expressing mutant KRAS.
Eight mice per group were inoculated s.c. with 1 × 106 A431-KRAS4bG12V cells, which are insensitive for EGFR signaling inhibition. A, Single treatment at day 0 with 5 mg/kg mAb. B, Single treatment at day 0, at indicated dose levels. Data shown are mean tumor volumes ± SEM.
Overdijk, M. B., Verploegen, S., van den Brakel, J. H., van Bueren, J. J. L., Vink, T., van de Winkel, J. G., ... & Bleeker, W. K. (2011). Epidermal growth factor receptor (EGFR) antibody-induced antibody-dependent cellular cytotoxicity plays a prominent role in inhibiting tumorigenesis, even of tumor cells insensitive to EGFR signaling inhibition. The Journal of Immunology, 1003926.
Figure 4 Histology and immunohistochemistry of biopsies from zalutumumab-injected skin treated with HuMab-10F8 or untreated.
Data shown are representative sections of skin biopsies of one subject for part III of the study. Biopsies were taken at day 14 after two injections with 100 µg of zalutumumab with [A, C, E, G, I, K] or without HuMab-10F8 [B, D, F, H, J, L]. A, B: HE staining; C, D: staining for EGFR; E–H: staining for macrophages and I–L: staining for neutrophils. Extensive influx of inflammatory cells in the vicinity of the hair follicle with histological signs of folliculitis was observed in zalutumumab-injected skin (right panels), whereas in the zalutumumab-injected skin treated with HuMab-10F8 (left panels) inflammatory cells were virtually absent and sebaceous glands and hair follicles showed normal histological features. Inflammatory infiltrate in the zalutumumab-injected skin was mainly composed of neutrophils (neutrophil elastase positive cells, J, L) and to a lesser extent of macrophages; (CD68 positive cells F, H). Scale bars are 100 µm (A–F, I, J) and 20 µm (G, H, K, L). G, H, K and L are magnifications of the squared areas indicated in E, F, I and J.
Bangsgaard, N., Houtkamp, M., Schuurhuis, D. H., Parren, P. W., Baadsgaard, O., Niessen, H. W., & Skov, L. (2012). Neutralization of IL-8 prevents the induction of dermatologic adverse events associated with the inhibition of epidermal growth factor receptor. PLoS One, 7(6), e39706.
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Afuco™ Anti-EGFR ADCC Recombinant Antibody (Zalutumumab), ADCC EnhancedThis product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to EGFR. Zalutumumab (proposed trade name HuMax-EGFr) is a fully human IgG1 monoclonal antibody (mAb) directed towards the epidermal growth factor receptor (EGFr).
CAT | Product Name | Application | Type |
---|---|---|---|
NABG-056 | Recombinant Anti-Mouse Egfr VHH Single Domain Antibody | ELISA, IHC, FC, FuncS | Llama VHH |
HPAB-AP881-YC | Recombinant Llama Anti-EGFR Single Domain Antibody (VHH122) | ELISA, FC, IP, FuncS | Llama VHH |
HPAB-AP882-YC | Recombinant Llama Anti-EGFR Single Domain Antibody (VHH205) | ELISA | Llama VHH |
HPAB-AP883-YC | Recombinant Llama Anti-EGFR Single Domain Antibody (VHH03) | ELISA | Llama VHH |
HPAB-AP884-YC | Recombinant Llama Anti-EGFR Single Domain Antibody (VHH139) | ELISA | Llama VHH |
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-020 | Anti-Human EGFR Recombinant Antibody (Panitumumab) | ELISA, IP, FC, FuncS, Neut, IF, ICC | IgG2 - kappa |
TAB-270MZ | Human Anti-EGFR Recombinant Antibody (TAB-270MZ) | ELISA | Human antibody |
TAB-278MZ-F(E) | Human Anti-EGFR Recombinant Antibody; Fab Fragment (TAB-278MZ-F(E)) | ELISA, WB | Human Fab |
PABX-053 | Recombinant Human Anti-EGFR Antibody (DL11) | WB, ELISA, FuncS | IgG |
PABX-052-S (P) | Recombinant Human Anti-EGFR Antibody scFv Fragment (Nimotuzumab) | WB, ELISA, FuncS | scFv |
CAT | Product Name | Application | Type |
---|---|---|---|
PFBL-080 | Human Anti-EGFR Recombinant Antibody; Fab Fragment (PFBL-080) | ELISA, WB, FuncS | Human Fab |
PSBW-171 | Mouse Anti-EGFR Recombinant Antibody; scFv Fragment (PSBW-171) | WB | Mouse scFv |
FAMAB-0094-YC-F(E) | Human Anti-EGFR Recombinant Antibody (clone F4); Fab Fragment | ELISA, WB, FC | Human Fab |
FAMAB-0202-CN-F(E) | Human Anti-EGFR Recombinant Antibody (clone E10); Fab Fragment | ELISA, WB | Human Fab |
HPAB-1443LY-F(E) | Human Anti-EGFR Recombinant Antibody (clone P1X); Fab Fragment | ELISA, WB | Human Fab |
CAT | Product Name | Application | Type |
---|---|---|---|
PABW-171 | Mouse Anti-EGFR Recombinant Antibody (PABW-171) | WB | Mouse IgG |
PFBW-088 | Mouse Anti-EGFR Recombinant Antibody (clone 7A7); Fab Fragment | ELISA, WB | Mouse Fab |
MRO-1834-CN | Rabbit Anti-EGFR Polyclonal Antibody (MRO-1834-CN) | WB, IF, IHC, FC | Rabbit IgG |
MRO-1835-CN | Rabbit Anti-EGFR Polyclonal Antibody (MRO-1835-CN) | WB, IF, IHC, FC | Rabbit IgG |
MRO-1836-CN | Rabbit Anti-EGFR Polyclonal Antibody (MRO-1836-CN) | WB, IF, IHC | Rabbit IgG |
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-0564CL-S(P) | Mouse Anti-EGFR Recombinant Antibody; scFv Fragment (TAB-0564CL-S(P)) | ELISA | Mouse scFv |
TAB-0565CL-S(P) | Mouse Anti-EGFR Recombinant Antibody; scFv Fragment (TAB-0565CL-S(P)) | ELISA | Mouse scFv |
TAB-0564CL-F(E) | Mouse Anti-EGFR Recombinant Antibody; Fab Fragment (TAB-0564CL-F(E)) | ELISA | Mouse Fab |
TAB-0565CL-F(E) | Mouse Anti-EGFR Recombinant Antibody; Fab Fragment (TAB-0565CL-F(E)) | ELISA | Mouse Fab |
TAB-271MZ-F(E) | Mouse Anti-EGFR Recombinant Antibody; Fab Fragment (TAB-271MZ-F(E)) | FuncS | Mouse Fab |
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-274MZ | Human Anti-EGFR Recombinant Antibody (TAB-274MZ) | FC | Humanized IgG |
TAB-300MZ | Human Anti-EGFR Recombinant Antibody (TAB-300MZ) | ELISA | Humanized IgG |
TAB-274MZ-S(P) | Human Anti-EGFR Recombinant Antibody; scFv Fragment (TAB-274MZ-S(P)) | FC | Humanized scFv |
TAB-300MZ-S(P) | Human Anti-EGFR Recombinant Antibody; scFv Fragment (TAB-300MZ-S(P)) | ELISA | Humanized scFv |
TAB-300MZ-F(E) | Human Anti-EGFR Recombinant Antibody; Fab Fragment (TAB-300MZ-F(E)) | ELISA | Humanized Fab |
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-302MZ | Human Anti-EGFR Recombinant Antibody (TAB-302MZ) | ELISA | Chimeric (mouse/human) IgG1 |
TAB-308MZ | Human Anti-EGFR Recombinant Antibody (TAB-308MZ) | FuncS | Chimeric antibody (mouse/human) |
TAB-272MZ-S(P) | Mouse Anti-EGFR Recombinant Antibody; scFv Fragment (TAB-272MZ-S(P)) | FuncS | Mouse scFv |
TAB-302MZ-S(P) | Mouse Anti-EGFR Recombinant Antibody; scFv Fragment (TAB-302MZ-S(P)) | ELISA | Mouse scFv |
TAB-308MZ-S(P) | Mouse Anti-EGFR Recombinant Antibody; scFv Fragment (TAB-308MZ-S(P)) | ELISA, FC | Mouse scFv |
CAT | Product Name | Application | Type |
---|---|---|---|
Gly-055LC | Recombinant Anti-Human EGFR Antibody (Fc glycosylation/High-mannose glycosylated) | ELISA | Chimeric antibody (mouse/human) |
Gly-144LC | Recombinant Anti-Human EGFR Antibody (Fc glycosylation) | ELISA | Humanized antibody |
CAT | Product Name | Application | Type |
---|---|---|---|
Gly-055LC-1 | Recombinant Anti-Human EGFR Antibody (Fc glycosylation/High-mannose glycosylated) | ELISA | Chimeric antibody (mouse/human) |
CAT | Product Name | Application | Type |
---|---|---|---|
Gly-167LC | Recombinant Anti-Human EGFR Antibody (Non-glycosylated) | ELISA | Human antibody |
CAT | Product Name | Application | Type |
---|---|---|---|
BRD-0183MZ | Chicken Anti-EGFR Polyclonal IgY | WB | Chicken antibody |
BRD-0668MZ | Chicken Anti-EGFR Polyclonal IgY | WB | Chicken antibody |
CAT | Product Name | Application | Type |
---|---|---|---|
MHC-LC773 | A*0201/Human EGFR (YLNTVQPTCV) MHC Tetramer | FCM | |
MHC-LC4545 | PE-DQB1*03:02/Human EGFR (SRALEEKKGNYVVTHG) MHC Tetramer | FCM | |
MHC-YF409 | A*02:01/Human EGF-R-479 (KLFGTSGQKT) MHC Pentamer | FCM |
CAT | Product Name | Application | Type |
---|---|---|---|
NEUT-722CQ | Rabbit Anti-EGFR Recombinant Antibody (clone CBL1011) | Neut | Rabbit IgG |
NEUT-723CQ | Mouse Anti-EGFR Recombinant Antibody (clone CBL931) | WB, IP, IHC, ICC, Neut | Mouse IgG1 |
NEUT-724CQ | Rabbit Anti-EGFR Recombinant Antibody (clone D1D4J) | IF, FC, WB, IP, Neut | Rabbit IgG |
CAT | Product Name | Application | Type |
---|---|---|---|
MOR-1101 | Hi-Affi™ Rabbit Anti-EGFR Recombinant Antibody (clone DS1101AB) | IHC-P | Rabbit IgG |
MOR-4520 | Hi-Affi™ Rabbit Anti-EGFR Recombinant Antibody (clone TH28DS) | IF, ICC, FC | Rabbit IgG |
MOR-4570 | Hi-Affi™ Rabbit Anti-EGFR Recombinant Antibody (clone TH82DS) | ELISA | Rabbit IgG |
MOR-4571 | Hi-Affi™ Rabbit Anti-EGFR Recombinant Antibody (clone TH83DS) | WB, IF, ICC, FC | Rabbit IgG |
MOR-4675 | Hi-Affi™ Rabbit Anti-EGFR Recombinant Antibody (clone TH189DS) | WB, IF, ICC, FC | Rabbit IgG |
CAT | Product Name | Application | Type |
---|---|---|---|
AFC-TAB-710 | Afuco™ Anti-EGFR ADCC Recombinant Antibody (Nimotuzumab), ADCC Enhanced | ELISA, IP, FC, FuncS, Neut, IF | ADCC enhanced antibody |
AFC-TAB-753 | Afuco™ Anti-EGFR ADCC Recombinant Antibody (Imgatuzumab), ADCC Enhanced | Neut, ELISA, IF, IP, FuncS, FC | ADCC enhanced antibody |
AFC-TAB-H35 | Afuco™ Anti-EGFR ADCC Recombinant Antibody (Futuximab), ADCC Enhanced | FuncS, IF, Neut, ELISA, FC, IP | ADCC enhanced antibody |
AFC-TAB-H49 | Afuco™ Anti-EGFR ADCC Recombinant Antibody (Modotuximab), ADCC Enhanced | FuncS, IF, Neut, ELISA, FC, IP | ADCC enhanced antibody |
AFC-TAB-020 | Afuco™ Anti-EGFR ADCC Recombinant Antibody (Panitumumab), ADCC Enhanced | ELISA, IP, FC, FuncS, Neut, IF | ADCC enhanced antibody |
CAT | Product Name | Application | Type |
---|---|---|---|
HPAB-S0020-YC-S(P) | Human Anti-EGFR Recombinant Antibody (clone E6.2); scFv Fragment | ELISA, Inhib | Human scFv |
HPAB-S0021-YC-S(P) | Human Anti-EGFR Recombinant Antibody (clone E6.3); scFv Fragment | ELISA, Inhib | Human scFv |
HPAB-S0022-YC-S(P) | Human Anti-EGFR Recombinant Antibody (clone E7.6.3); scFv Fragment | ELISA, Inhib, FuncS | Human scFv |
HPAB-2059-FY-S(P) | Mouse Anti-EGFR Recombinant Antibody (clone L2-12B); scFv Fragment | FC, ELISA | Mouse scFv |
HPAB-2060-FY-S(P) | Mouse Anti-EGFR Recombinant Antibody (clone L3-11D); scFv Fragment | FC, ELISA | Mouse scFv |
There are currently no Customer reviews or questions for TAB-040. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.